JNJ · News · 20260930N

Product / Drug Pipeline Progress

JOHNSON & JOHNSON · 2026-09-30 · Importance 23 · Surprise 24

Johnson & Johnson reported two-year IMAAVY data in generalized myasthenia gravis (gMG), including outcomes for adolescents. The data showed sustained disease control, functional improvement, and a consistent safety profile. The findings support IMAAVY’s role in Johnson & Johnson’s next-generation immunology strategy and highlight potential adult gMG opportunities as patients transition between therapies.

Key facts

• Recent positive clinical trial findings for Tremfya and Carvykti were announced on September 25th. source
• Johnson & Johnson released new two-year IMAAVY data for generalized myasthenia gravis (gMG), including adolescent outcomes, demonstrating sustained disease control, functional improvement, and a consistent safety profile. source
• The company's robotic surgical system, Ottava, could become a meaningful growth driver. source